Abstract
The virus SARS-COV-2 caused disease COVID-19 has been declared a pandemic by WHO. Currently, over 210 countries and territories have been affected. Careful, well-designed drugs and vaccine for the total elimination of this virus seem to be the need of the hour. In this context, the invivo mathematical modelling studies can be extremely helpful in understanding the efficacy of the drug interventions. These studies can also help understand the role of the crucial inflammatory mediators and the behaviour of immune response towards this novel coronavirus. Motivated by these facts, in this paper, we study the invivo dynamics of Covid-19. The results obtained here are inline with some of the clinical findings for Covid-19. This invivo modelling study involving the crucial biomarkers of Covid-19 is the first of its kind and the results obtained from this can be helpful to researchers, epidemiologists, clinicians and doctors who are working in this field.
Introduction
While many COVID-19 models focus on epidemiological spread, this study investigates the biological battleground inside an infected individual. Specifically, it addresses the "cytokine storm"—the uncontrolled systemic inflammatory response leading to Acute Respiratory Distress Syndrome (ARDS). By creating a model that includes specific biomarkers (like IL-6 and TNF-$\alpha$), the authors bridge the gap between clinical observations and mathematical theory to evaluate the performance of different drug interventions, such as antivirals and immunotherapy.
Methods
The study employs two distinct Ordinary Differential Equation (ODE) models to simulate the interaction between SARS-CoV-2 and the human immune system.
- Model 1 (Natural History): Tracks healthy Type II Pneumocytes ($S$), infected cells ($I$), and viral load ($V$). It incorporates removal rates of infected cells and viruses mediated by six inflammatory cytokines: IL-6, TNF-$\alpha$, INF-$\alpha$, CCL5, CXCL8, and CXCL10.
- Model 2 (Interventions): Introduces control variables for drug interventions:
- $u_{11}$ and $u_{12}$: Enhancers of the innate immune response to clear infected cells and free viruses.
- $u_2$: Antiviral drugs (e.g., Remdesivir, Ivermectin) that inhibit viral replication.
The parameters used in these models are detailed in the table below:
The researchers utilized Stability Analysis to identify the basic reproduction number ($R_0$) and Optimal Control Theory (Pontryagin’s Maximum Principle) to determine ideal drug dosages over a 30-day period. Parameters were estimated based on published clinical data, ensuring the model reflects known characteristics like peak viremia timing and target cell depletion.
Results
Stability and Sensitivity
The system exhibits a transcritical bifurcation at $R_0 = 1$. If $R_0 < 1$, the infection is cleared; if $R_0 > 1$, it reaches an infected equilibrium. Sensitivity analysis identified the viral burst rate ($\alpha$) and the natural death rate of the virus ($\mu_1$) as the most critical parameters influencing recovery.
Treatment Efficacy
- Combination Therapy: The most effective strategy involves using all three drug types simultaneously, which reduced viral load to near zero by day 7.
- Antiviral Performance: Replication inhibitors like Ivermectin showed a substantial decrease in viral load from day 2, consistent with in vitro findings of a 5000-fold reduction in viral RNA.
- Rebound Risk: Simulations revealed that using only antiviral replication inhibitors ($u_2$) might lead to an initial drop followed by a viral surge after day 20, highlighting the necessity of immune-boosting co-treatments.
Conclusion
This in-vivo mathematical model provides a framework for understanding the complex interplay between SARS-CoV-2 and the host's inflammatory response. The findings emphasize that a synergistic approach—combining antivirals with immune-system boosters—is superior for achieving total viral elimination and preventing late-stage rebounds. Future work will aim to refine biomarker feedback loops and incorporate a broader range of interventions like monoclonal antibodies.
Summary updated